Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.

① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.

cls.cnDec 24, 2024 17:16

KING INTL INV: Interim Report 2024

HKEXDec 24, 2024 16:09 · Announcements

KING INTL INV (00928.HK) has appointed Leng Yueying Tan as Executive Director and Chairman.

Gelonghui, December 20th – KING INTL INV (00928.HK) announced that Mr. Wang Mengyao resigned as the chairman of the Board of Directors, and Mr. Leng Yueyingtan was appointed as the executive director and chairman, effective from December 20, 2024.

Gelonghui FinanceDec 20, 2024 20:26

Express News | The USA Biological Security Act was not included in the CR bill.

BreakingsDec 18, 2024 15:53

The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!

Industry pessimistic expectations may improve.

Gelonghui FinanceDec 9, 2024 12:10

How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.

① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.

cls.cnDec 8, 2024 16:48